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formed remotely using vendor-specific hardware and softwara. In this study,
we examined the technical feasibility of displaying diagnostic quality images
on a remote site PC with an Internet WEB browaer (Netscape 2.02). Blinded
review of 26 consecutive studies establishad an interpretive concordance of
83% for any abnormality, 81Y0for multivesael ischemia, and 85% forterrftoty
of abnormality when compared with images read from films. Technical issuea
involved were: 1) Development of a display format for presentation of axial
slices, polar maps with quantitative information, and planar imageson a 1020
x 620, 6 bit display; 2) Security of the WEB aite; 3) Image conversion from
raw data to 6 bit grey scale (GIF image format); 4) Average download time of
104 + 6 seconds using a 26.6 kbs modem with V34 compression; 5) Display
on a Pentium 100 with a 1 Mb video card; 6) Video card display settings of 8
bit color and 600 x 600 resolution. Image quality scored by two independent,
expati obsewere on a scale of 1-5 (1 = inadequate; 2 = poor; 3 = adequate;
4 = good; 5 = auperfor) ranged from 3 to 4 (average value = 3.7).
Corrc/usion:This investigation establishes the technical feeeibilityof inter-
pretation of images over the Internet using a PC and a WEB browser. While
the current configuration permits reasonably high interpretive concordance
relative to traditional films, incorporation of additional data (such as rotating
projection images and pertinent aspects of a patient’s history) and a higher
quality image display medium may further improve results.
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m1074118 Design, Synthesis snd In Vivo Actions of a Novel
Chimeric Peptide to B-Type (BNP) and C-Type
(CNP) Natriuretic Peptidea
W.L. Chau, M. Jougaaaki, C.-M. Wei, J.C. Burnett, Jr.. Mayo Clinic,
Rochestec MN, USA
CNP,a member of the natriuretic peptide system (NPS) of endothelial origin,
is a potent venodilator with minimal natriuretic actions. CNP exerts vascular
actions via generation of cGMP after binding to the NPR-B receptor. BNP,
a member of the NPS of myocardial origin, is the most potent natrfuretic
peptide. BNP mediates its natriuretic effect via the NPR-A receptor. Both
CNP and BNP posaeae a 17-amino acid ring structura, but BNP has a 6-
amino acid COOH-terminus which CNP Iacka. This atudy was undertaken
to investigate the in vivo actions of a novel 26-amino acid chimeric paptide
termed “CB-NP”. This peptide possesses the 22-amino acid structure of
CNP and the 6-amino acid COOH terminus of BNP.CB-NP was synthesized
uaing FLMC chemistry on a peptide synthesizer and purified by reverse
phase HPLC. In 5 anesthetized dogs, cardiorenal function was measured
in reaponse to CB-NP (50 ngkdmin IV) followed by co-infusion of HS-142-
1, a dual inhibitor of NPR-A and B receptors (3 mglkg IV bolua). CB-NP
decreased right atrlal pressure (-1.2+ 0.3 to –2.2 + 0.4 mmHg, p < 0.05)
and cardiac output (3.6 + 0.2 to 3.1 + 0.3 l/rein, p < 0.05) consistent with
a decrease cardiac preload. HS-142-1 did not reverae these effects. CB-NP
wee marfradly natriuretic with increaaea in glomerular filtration rate (38 + 4
to 52 & 5 ml/min, p < 0.05), urinary sodium excretion (65&24 to 240 +76
mEq/min, p < 0.05), fractional sodium excretion (1.1 + 0.4 to 3.3 + 1.O%,p
< 0.05) and a decrease in distal fractional reabsorption of sodium (96.4 +
1.0 to 91.2+ 1.8Y0,p < 0.05). CB-NP increaaed plasma cGMP (3.1 + 0.9 to
7.1 +2.8 pmol/ml, p e 0.05) and urinary cGMP excretion (733 + 124to 1843
+ 356 pmol/ml, p -=0.05). HS-142-I abolished all these effects. The current
study suggeats that CB-NP poaseases the venodilating actions of CNP and
the natrfuretic actions of BNP which are secondary to unique co-activation
of both NPR-A and B receptors. This unique paptide may have therapeutic
potential in cardiorenal disease statea.
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Angiotenain II (ANG H)induces cell hypertrophy and natriuratic peptide (NP)
production supporting a role for atrial (ANP) and brain (BNP) natriuretic
paptidea as serum markers for left ventricular hypartrophy (LVH). The effect
of chronic ACE inhibition (ACEI) in congestive hearl failure (CHF) upon LVH
and plasma NPa remaina poorly defined. We tested the hypothesis that
inhibition of ANG II with ACEI during the progression of CHF would prevent
LVHand attenuate increases in circulating ANP and BNP,and that these NPs
would be powerful serum markers for LVHwith and without ACEI during CHF.
CHF wee produ@ by rapid ventricular pacing in the preaence (n = 6, CHF+
ACEI) andabaence (n =6, CHF) of enalapril (10 mg PObid). Plasma NPsand
ANG IIwera determined during the progression of CHF. Left ventricular mass
index (LVMI) was determined at autopsy. ACEI prevented the late incraase
in ANG II eeaociated with CHF (A 10 + 3 vs 143 + 67, P < 0.05), and
attenuated the increase in ANP and BNP during the progression of CHF.
without differences in cardiac filling pressures. * denotes p <0.05 vs CHF
CHF CHF + ACEI
BL Early Late BL Early Late
ANP (p@ml) 43i 11 233+ 64 416&93 50+10 140* 41 235& 39*
BNP (pg/ml) 19+6 77 l 2O 155+ 32 20+6 20* 7* 54* 7*
ACEI preventad the increase in LVMI (4.2 + 0.1 VS4.9 + 0.2 m~kg TBW,
p < 0.05) and ANP and BNP correlated with LVMI (r= 0.65, p <0.01 and
r = 0.87, p <0.001, respectively). We conclude that endogenous ANG II
modulates LVH and the activation of circulating NPs in experimental CHF.
Additionally, ACEI prevents LVH and activation NPs in experimental CHF,
and both ANP and BNP are powerful markera of LVH in the presence and
absence of ACEI.
1074-120 Quantitative Expression of the Tissue Renin
Angiotensin System in Left Ventricles with
Aofiic Stenosis Compared to Normal Hearta
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A. Sch6mig. Deutsches Herzzentrum and 1.Med. Klinik, Klinikum rechts
derlaac TachnischeUniverait#, Munich, Germany
Angiotensin II is a potent growth factor in cardiovascular tissues. It’s local
effects are determined by the supply with angiotensinogen, which is con-
verted via ACE and chymase to the biological active compeund. Moat of it’s
known effects are mediated by tha AT1-receptor.The AT2-receptor is mainly
expressed in fetal tissues and wound haaling, indicating It’apredominant role
in growth, development and differentiation.
We investigated the expression of the tisaue renin angiotenein system
(tissue RAS) intissuesamples from Ieftventriciea with aorticstenosis (n = 12)
COMpSrSdto frOMMlleftventricles from not transplantad donor hearts (n = 6)
by quantitative reverse transcription-polymersae chain reaction (RT-PCR).
Recently, we described the construction of a multistendard cRNA, which
enables the quantification of the gene expression of the different components
of the human tissue RAS by coamplification with specific oligonucleotide
primers.
Resu/ts: the AT1-receptor expression decreased markedly in left ventri-
cles with aortic stenosia (p < 0.01), while there was no aignificsnt difference
in the AT2-racaptor expression. The angiotensinogen expression is signifi-
cantly enhanced compared to normal hearts. No aignificent differenoea were
found in the expression of ACE and chymaae.
Conclusion: The study revealed a different regulation of the AT-reoeptor
subtypes in left ventricular hypertrophy caused by aortic stenosis, which
is associated by an enhanced expression of the angiotensin II precursor
angiotensinogen.
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The Endothelin B receptor (ETs) isexpreas6d in neural and endothelial cells.
It playsan important role inthedevelopment of theneursd crest and isooupled
to the production of factors involved in normal endothelial’functions such as
nitric oxide. Its absence or downregulation likely plays a key role in the
development of pulmonaty hypertension and other instances of endothelial
dysfunction. To understand ikaregulation, we obtained mouse ETB genomic
clones and characterized a 1.6 kb fragment that contained all of exon I -
including 0.2 kb of 5’ untranslated region (UTR)- and approximately 0.66 kb
of the 5’ flanking region. The transcription initiation site is located at –200
relativa to the translational atart site. Transfaotion experiments showed that
this fragment functioned as a specific promoter of a Iuciferase reporter gene
in P19 neural cells expressing ETs. Serial deletions between –660 to –160
led to a > 12-fold increase in Iucifersse activity. The deletion of -160 to –75
(including a 40 bp long region of 83% homology between the mouse and
tha human genes) resulted in a 95% loss of activity of the reporter gene. In
conclusion: 1)strong silencer elements are present in the 5’ flanking region of
